

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 June 2022 (30.06.2022)



(10) International Publication Number
WO 2022/137125 A1

(51) International Patent Classification:

A61K 31/201 (2006.01) A61K 38/00 (2006.01)
A61K 31/202 (2006.01) A61K 45/06 (2006.01)
A61K 31/519 (2006.01) A61P 1/16 (2006.01)
A61K 31/575 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/IB2021/062115

(22) International Filing Date:

21 December 2021 (21.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/128,996 22 December 2020 (22.12.2020) US

(71) Applicant: **NORTHSEA THERAPEUTICS B.V.**
[NL/NL]; Paasheuvelweg 25-C6, 1105 BP Amsterdam
(NL).

(72) Inventor: **FRASER, David Alan**; Oksehovedveien 12,
1365 Blommenholm (NO).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(54) Title: COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS

(57) Abstract: The present disclosure provides a combination therapy for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH), wherein the combination therapy comprises an unsaturated fatty acid with an oxygen incorporated in the β -position and an α -substituent and at least one additional active agent chosen from a glucagon-like peptide 1 receptor agonist, an acetyl-CoA carboxylase inhibitor, and a farnesoid X receptor agonist.

WO 2022/137125 A1